STOCK TITAN
  1. Home
  2. Sec-filings
  3. GH
  4. [Form 4] Guardant Health, Inc. Insider Trading Activity

Guardant Health (GH) CCO gains shares through RSU vesting and tax withholding

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Guardant Health, Inc. Chief Commercial Officer Chris Freeman exercised performance-based and time-based restricted stock units into common stock. On March 15, 2026, 15,426 performance-based RSUs and 1,402 RSUs converted into an equal number of common shares at a conversion price of $0.00 per share. To cover tax withholding obligations on this vesting, 7,127 common shares were retained by the company at $85.49 per share, as a tax-withholding disposition rather than an open-market sale. Following these transactions, Freeman directly holds 53,571 shares of Guardant Health common stock. The performance-based award was granted on June 7, 2023 with a three-year performance metric, and the RSU award was granted on June 9, 2023 with vesting over three years.

Positive

  • None.

Negative

  • None.
Insider Freeman Chris
Role Chief Commercial Officer
Type Security Shares Price Value
Exercise Performance-Based Restricted Stock Units 15,426 $0.00 --
Exercise Restricted Stock Units 1,402 $0.00 --
Exercise Common Stock 15,426 $0.00 --
Exercise Common Stock 1,402 $0.00 --
Tax Withholding Common Stock 7,127 $85.49 $609K
Holdings After Transaction: Performance-Based Restricted Stock Units — 0 shares (Direct); Restricted Stock Units — 1,402 shares (Direct); Common Stock — 59,296 shares (Direct)
Footnotes (1)
  1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. This represents a performance-based restricted stock unit award granted on June 7, 2023 with a 3-year performance metric. The second tranche metric was achieved and the shares vested on March 15, 2026. Not applicable for Restricted Stock Units. This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Freeman Chris
(Last) (First) (Middle)
3100 HANOVER STREET
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/15/2026 M 15,426 A $0 59,296 D
Common Stock 03/15/2026 M 1,402 A $0 60,698 D
Common Stock 03/15/2026 F 7,127(1) D $85.49 53,571 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance-Based Restricted Stock Units $0 03/15/2026 M 15,426 (2) (3) Common Stock 15,426 $0 0 D
Restricted Stock Units $0 03/15/2026 M 1,402 (4) (3) Common Stock 1,402 $0 1,402 D
Explanation of Responses:
1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
2. This represents a performance-based restricted stock unit award granted on June 7, 2023 with a 3-year performance metric. The second tranche metric was achieved and the shares vested on March 15, 2026.
3. Not applicable for Restricted Stock Units.
4. This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Remarks:
/s/ John G. Saia, as attorney-in-fact for Chris Freeman 03/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Guardant Health (GH) report for Chris Freeman?

Chris Freeman exercised performance-based and time-based restricted stock units into common stock. On March 15, 2026, 15,426 performance-based RSUs and 1,402 RSUs converted into common shares, with some shares withheld to satisfy tax obligations.

How many Guardant Health shares does Chris Freeman hold after this Form 4?

After the reported transactions, Chris Freeman directly holds 53,571 shares of Guardant Health common stock. This reflects RSU and performance-based RSU vesting on March 15, 2026, net of shares retained by the company for tax withholding obligations.

Was there an open-market sale in Chris Freeman’s Guardant Health Form 4?

No open-market sale is reported. The disposition of 7,127 shares classified under code F represents shares retained by Guardant Health to cover tax withholding obligations related to RSU vesting, rather than a discretionary market sale by Chris Freeman.

What are the terms of Chris Freeman’s performance-based RSUs at Guardant Health (GH)?

The performance-based restricted stock unit award was granted on June 7, 2023 with a three-year performance metric. According to the disclosure, the second tranche metric was achieved and those shares vested on March 15, 2026, triggering conversion into common stock.

How do Chris Freeman’s time-based RSUs at Guardant Health vest?

The restricted stock unit award was granted on June 9, 2023 and vests over three years. One-third of the shares vested on June 15, 2024, and the remaining two-thirds vest in equal quarterly installments over the following two-year period.

What price was used for Guardant Health shares withheld for Chris Freeman’s taxes?

For the tax-withholding disposition, 7,127 Guardant Health common shares were retained by the company at a price of $85.49 per share. The filing notes the amount retained was not in excess of the applicable tax liability for the vesting.